Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure

Background: Empagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease. We sought to elucidate effect empagliflozin as an add-on therapy on decongestion renal function admitted acute decompensated failure. Methods: The study was terminated early due COVID-19 pandemic. enrolled 59 consecutive Patients were randomly assigned receive either (n=30) or conventional glucose-lowering (n=29). performed laboratory tests at baseline 1, 2, 3, 7 days after randomization. Percent change plasma volume between admission subsequent time points calculated using Strauss formula. Results: There no significant differences left ventricular ejection fraction serum NT-proBNP (N-terminal pro-B-type natriuretic peptide), hematocrit, creatinine levels groups. Seven randomization, level significantly lower group than ( P =0.040), hemoconcentration (≥3% absolute increase hematocrit) more frequently observed =0.020). decrease percent larger randomization =0.017). incidence worsening (an ≥0.3 mg/dL) did not differ Conclusions: In this exploratory analysis, achieved effective without increased Registration: URL: https://www.umin.ac.jp/ctr/index.htm ; Unique identifier: UMIN000026315.